Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Use of canine cells in flu vaccine development debated

Executive Summary

The Vaccines and Related Biological Products Advisory Committee will discuss the use of Madin-Darby canine kidney cells in the manufacturing of live attenuated influenza virus vaccines. When the committee met in 2005 to discuss using the cells, it overwhelmingly agreed that companies should move forward with development, but also recommended that studies be done in animals inoculated with the final vaccine product (1"The Pink Sheet," Nov. 21, 2005, p. 22). It also recommended monitoring patients because of potential oncogenic risks from the tumorigenic canine cell lines

You may also be interested in...

Canine Cell-Based Flu Vaccines Should Have Patient Follow-Up, Cmte. Says

Patient follow-up is needed for recipients of influenza vaccine produced using Madin Darby canine kidney cells, FDA's Vaccines & Related Biological Products Advisory Committee said

Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date

ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.

COVID-19 Shows Remote Monitoring Can Work For Pre-Cert Program

In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts